Tyler J. Lefevre

Tyler J. Lefevre

Auto-generated profile, based on publicly available information

Tyler J. Lefevre

AstraZeneca

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2021 in Molecular Cell
Verified
Journal Article
Closed access
KKKevin M. Knight
Kevin M. Knight
SGSoumadwip Ghosh
Soumadwip Ghosh
SCSharon L. Campbell
Sharon L. Campbell
TLTyler J. Lefevre
Tyler J. Lefevre
ROReid H.J. Olsen
Reid H.J. Olsen
HDHenrik G. Dohlman
Henrik G. Dohlman

5 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
KKKevin M. Knight
Kevin M. Knight
BKBrian E. Krumm
Brian E. Krumm
NKNicholas J. Kapolka
Nicholas J. Kapolka
WLW. Grant Ludlam
W. Grant Ludlam
MCMeng Cui
Meng Cui
HDHenrik G. Dohlman
Henrik G. Dohlman
Many neurotransmitter receptors activate G proteins through exchange of GDP for GTP. The intermediate nucleotide-free state has eluded characterization, due largely to its inherent instability. Here we characterize a G protein variant associated with a rare neurological disorder in humans. GαoK46E has a charge reversal that clashes with the phosphate groups of GDP and GTP. As anticipated, the purified protein binds poorly to guanine nucleotides yet retains wild-type affinity for G protein βγ subunits. In cells with physiological concentrations of nucleotide, GαoK46E forms a stable complex with receptors and Gβγ, impeding effector activation. Further, we demonstrate that the mutant can be easily purified in complex with dopamine-bound D2 receptors, and use cryo-electron microscopy to determine the structure, including both domains of Gαo, without nucleotide or stabilizing nanobodies. These findings reveal the molecular basis for the first committed step of G protein activation, establish a mechanistic basis for a neurological disorder, provide a simplified strategy to determine receptor-G protein structures, and a method to detect high affinity agonist binding in cells.

23 March 2024 in Journal of Biological Chemistry
Verified
Journal Article
Open access
TLTyler J. Lefevre
Tyler J. Lefevre
WWWenyuan Wei
Wenyuan Wei
EMElizaveta Mukhaleva
Elizaveta Mukhaleva
SVSai Pranathi Meda Venkata
Sai Pranathi Meda Venkata
NCNaincy R. Chandan
Naincy R. Chandan
ASAlan V. Smrcka
Alan V. Smrcka
Highly homologous members of the Gαi family, Gαi1-3, have distinct tissue distributions and physiological functions, yet their biochemical and functional properties are very similar. We recently identified PDZ-RhoGEF (PRG) as a novel Gαi1 effector that is poorly activated by Gαi2. In a proteomic proximity labeling screen we observed a strong preference for Gαi1 relative to Gαi2 with respect to engagement of a broad range of potential targets. We investigated the mechanistic basis for this selectivity using PRG as a representative target. Substitution of either the helical domain (HD) from Gαi1 into Gαi2 or substitution of a single amino acid, A230 in Gαi2 with the corresponding D in Gαi1, largely rescues PRG activation and interactions with other potential Gαi targets. Molecular dynamics simulations combined with Bayesian network models revealed that in the GTP bound state, separation at the HD-Ras-like domain (RLD) interface is more pronounced in Gαi2 than Gαi1. Mutation of A230 to D in Gαi2 stabilizes HD-RLD interactions via ionic interactions with R145 in the HD which in turn modify the conformation of Switch III. These data support a model where D229 in Gαi1 interacts with R144 and stabilizes a network of interactions between HD and RLD to promote protein target recognition. The corresponding A230 in Gαi2 is unable to stabilize this network leading to an overall lower efficacy with respect to target interactions. This study reveals distinct mechanistic properties that could underly differential biological and physiological consequences of activation of Gαi1 or Gαi2 by G protein-coupled receptors.

8 August 2025 in mAbs
Verified
Journal Article
Open access
TLTyler J. Lefevre
Tyler J. Lefevre
JCJenna G. Caldwell
Jenna G. Caldwell
AGAustin Gallegos
Austin Gallegos
QDQun Du
Qun Du
EHErin Houston
Erin Houston
REReza Esfandiary
Reza Esfandiary
Subcutaneous (SC) delivery of therapeutic antibodies can offer multiple benefits to patients and healthcare providers, including convenience, time savings, and cost reduction. To improve the SC injection experience, drug developers may seek a low injection volume (1-2 mL), which for some antibody drugs necessitates a high concentration solution (≥100 mg/mL) to meet dosage requirements. Several molecular-level challenges hinder the development of high concentration antibody drug products, including high viscosity caused by reversible self-association (RSA). Here, we take an enhanced rational design approach to reduce RSA via protein engineering. Using hydrogen-deuterium exchange mass spectrometry (HDX-MS), we identified potential self-interaction hotspots on the surface of an in-house IgG1 which has known viscosity issues at high concentration. Then, using in silico antibody modeling, we identified sites near the complementary-determining regions for targeting by rational mutagenesis, which included predicted patches of charge or hydrophobicity within or near peptides highlighted by HDX-MS. Screening of nearly 70 variants using dynamic light scattering (DLS) and affinity capture self-interaction nanospectroscopy (AC-SINS) at low concentration showed decreased self-interaction in many variants. Viscosity at 150 mg/mL was reduced by 70% for 13 variants, while two of these variants designed to reduce surface hydrophobicity were found to retain antigen binding compared to the parent antibody. DLS and AC-SINS measurements of self-association were found to correlate with viscosity at high concentration, reinforcing their utility as effective low-concentration screening tools for viscosity. This work demonstrates an enhanced rational mutagenesis strategy informed by the combination of HDX-MS for self-association and in silico predictions of surface properties. The resulting variants are a vast improvement on the parent antibody's viscosity issues and offer insight into the mechanism of self-association.

12 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
TLTyler J. Lefevre
Tyler J. Lefevre
WWWenyuan Wei
Wenyuan Wei
EMElizaveta Mukhaleva
Elizaveta Mukhaleva
SVSai Pranathi Meda Venkata
Sai Pranathi Meda Venkata
NCNaincy R. Chandan
Naincy R. Chandan
ASAlan V. Smrcka
Alan V. Smrcka
Highly homologous members of the Gα i family, Gα i1-3 , have distinct tissue distributions and physiological functions, yet the functional properties of these proteins with respect to GDP/GTP binding and regulation of adenylate cyclase are very similar. We recently identified PDZ-RhoGEF (PRG) as a novel Gα i1 effector, however, it is poorly activated by Gα i2 . Here, in a proteomic proximity labeling screen we observed a strong preference for Gα i1 relative to Gα i2 with respect to engagement of a broad range of potential targets. We investigated the mechanistic basis for this selectivity using PRG as a representative target. Substitution of either the helical domain (HD) from Gα i1 into Gα i2 or substitution of a single amino acid, A230 in Gα i2 to the corresponding D in Gα i1 , largely rescues PRG activation and interactions with other Gα i targets. Molecular dynamics simulations combined with Bayesian network models revealed that in the GTP bound state, dynamic separation at the HD-Ras-like domain (RLD) interface is prevalent in Gα i2 relative to Gα i1 and that mutation of A230 s4h3.3 to D in Gα i2 stabilizes HD-RLD interactions through formation of an ionic interaction with R145 HD.11 in the HD. These interactions in turn modify the conformation of Switch III. These data support a model where D229 s4h3.3 in Gα i1 interacts with R144 HD.11 stabilizes a network of interactions between HD and RLD to promote protein target recognition. The corresponding A230 in Gα i2 is unable to form the “ionic lock” to stabilize this network leading to an overall lower efficacy with respect to target interactions. This study reveals distinct mechanistic properties that could underly differential biological and physiological consequences of activation of Gα i1 or Gα i2 by GPCRs.